A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Bleomycin
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Aug 2019 Planned initiation date changed from 1 Dec 2018 to 1 Dec 2019.
- 07 Aug 2018 Planned initiation date changed from 28 Feb 2018 to 1 Dec 2018.
- 06 Mar 2018 New trial record